| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2006.08.4046 |
| P698 | PubMed publication ID | 17634485 |
| P50 | author | Krzysztof Jeziorski | Q22114810 |
| Camillo Porta | Q37393105 | ||
| Robert Gish | Q47723303 | ||
| Lynn G Feun | Q93101401 | ||
| P2093 | author name string | John Leighton | |
| Ronald Feld | |||
| Paul Ruff | |||
| Adina Croitoru | |||
| Gerard T Kennealey | |||
| José Gallo | |||
| Lucian Lazar | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | randomized controlled trial | Q1436668 |
| patient | Q181600 | ||
| hepatocellular carcinoma | Q1148337 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 3069-3075 | |
| P577 | publication date | 2007-07-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin | |
| P478 | volume | 25 |
| Q85364824 | A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma |
| Q46574374 | A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma |
| Q42004327 | Accomplishments in 2007 in the management of hepatobiliary cancers. |
| Q39601411 | Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization |
| Q30423781 | Advances in non-surgical management of primary liver cancer |
| Q91617824 | All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized co |
| Q58701446 | Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma |
| Q30479629 | Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma |
| Q39124020 | Association between reversal of multidrug resistance by methyl jasmonate and P-glycoprotein ATPase activity in hepatocellular carcinoma |
| Q44975845 | Availability of Experimental Therapy Outside Oncology Randomized Clinical Trials in the United States |
| Q64988530 | Berberine-loaded Janus gold mesoporous silica nanocarriers for chemo/radio/photothermal therapy of liver cancer and radiation-induced injury inhibition. |
| Q44114271 | Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series |
| Q35495325 | Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions |
| Q89623916 | Controversies in the management of hepatocellular carcinoma |
| Q28540248 | DNA damage induces down-regulation of Prp19 via impairing Prp19 stability in hepatocellular carcinoma cells |
| Q57788769 | DNMTs inhibitor SGI-1027 induces apoptosis in Huh7 human hepatocellular carcinoma cells |
| Q35085657 | Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma |
| Q41493235 | Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model. |
| Q37798817 | Developing better treatments in hepatocellular carcinoma |
| Q44481786 | Diagnosis of and therapy for hepatocellular carcinoma |
| Q39432374 | Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma |
| Q35856029 | Downregulation of Vascular Endothelial Growth Factor Enhances Chemosensitivity by Induction of Apoptosis in Hepatocellular Carcinoma Cells. |
| Q38161583 | Doxorubicin -eluting beads in the treatment of liver carcinoma |
| Q36165081 | Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies |
| Q37293105 | Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience |
| Q37828640 | Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies |
| Q39366121 | Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma |
| Q41171803 | Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology |
| Q42617015 | Evolution of systemic therapy of advanced hepatocellular carcinoma |
| Q58034993 | Fatty acid composition and biological activities of Isochrysis galbana T-ISO, Tetraselmis sp. and Scenedesmus sp.: possible application in the pharmaceutical and functional food industries |
| Q47140323 | Fibrinogen and C-reactive protein score is a prognostic index for patients with hepatocellular carcinoma undergoing curative resection: a prognostic nomogram study |
| Q35872080 | Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery |
| Q37729748 | Folate-targeted paclitaxel-conjugated polymeric micelles inhibits pulmonary metastatic hepatoma in experimental murine H22 metastasis models |
| Q33631525 | Fragment-based discovery of novel thymidylate synthase leads by NMR screening and group epitope mapping |
| Q38161384 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan |
| Q33404756 | Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours |
| Q39289689 | Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. |
| Q36171275 | Hepatocellular carcinoma: natural history, current management, and emerging tools |
| Q37745961 | High expression of GFAT1 predicts unfavorable prognosis in patients with hepatocellular carcinoma |
| Q37183451 | Immunotherapy for renal cell cancer in the era of targeted therapy |
| Q41828504 | In vitro three dimensional culture of hepatocellular carcinoma to measure prognosis and responsiveness to chemotherapeutic agents |
| Q92353495 | Insights into the success and failure of systemic therapy for hepatocellular carcinoma |
| Q41017463 | Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway |
| Q34293068 | Investigational approaches for mesothelioma |
| Q57156887 | LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling |
| Q36917485 | Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. |
| Q38686790 | Locoregional and systemic therapy for hepatocellular carcinoma |
| Q38068868 | Long-term progression-free survival in a case of hepatocellular carcinoma with vertebral metastasis treated with a reduced dose of sorafenib: Case report and review of the literature |
| Q89111230 | Low expression of WW domain-containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection |
| Q28236063 | Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer |
| Q39720049 | Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer |
| Q37236004 | Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma |
| Q38749275 | MicroRNA31-NDRG3 regulation axes are essential for hepatocellular carcinoma survival and drug resistance |
| Q92296475 | Minimally invasive gas embolization using acoustic droplet vaporization in a rodent model of hepatocellular carcinoma |
| Q37370027 | Molecular targeted therapy for hepatocellular carcinoma |
| Q37779804 | Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib |
| Q43234592 | New pharmacological developments in the treatment of hepatocellular cancer |
| Q64112569 | Oncolytic viro-chemotherapy exhibits antitumor effect in laryngeal squamous cell carcinoma cells and mouse xenografts |
| Q41843121 | Optimization modeling of single-chain antibody against hepatoma based on similarity algorithm |
| Q37174945 | Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection |
| Q42971014 | Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma. |
| Q92462428 | Preclinical verification of the efficacy by targeting peptide-linked liposomal nanoparticles for hepatocellular carcinoma therapy |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q38864396 | Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment |
| Q64913937 | Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. |
| Q33631372 | Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study |
| Q91660574 | Psoralen inhibits malignant proliferation and induces apoptosis through triggering endoplasmic reticulum stress in human SMMC7721 hepatoma cells |
| Q35832116 | RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma |
| Q38128370 | Radiofrequency ablation for hepatocellular carcinoma |
| Q37945636 | Raltitrexed in mesothelioma |
| Q55266511 | Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. |
| Q40159389 | Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology |
| Q94543854 | Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors |
| Q92830327 | Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial |
| Q42343451 | Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future |
| Q37127099 | Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study |
| Q37734197 | Systemic therapy for advanced hepatocellular carcinoma: past, present, and future |
| Q37135733 | Systemic therapy in hepatocellular carcinoma |
| Q26865844 | Systemic therapy of hepatocellular carcinoma: current status and future perspectives |
| Q33854034 | Systemic treatment of hepatocellular carcinoma: Past, present and future |
| Q34632966 | Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. |
| Q35045419 | The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance |
| Q39347890 | The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection. |
| Q38804626 | The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. |
| Q38236876 | Treatment of intermediate-stage hepatocellular carcinoma |
| Q94340226 | UEG Week 2016 Poster Presentations |
| Q28073477 | Understanding the role of PIN1 in hepatocellular carcinoma |
| Q92577497 | Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit |
| Q35921211 | β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. |
Search more.